4-((1-Hydroxy-1,3-dihydrobenzo-[c][1,2]oxaborol-5-yl)oxy)benzonitrile

4-[(1,3-Dihydro-1-hydroxy-2,1-benzoxaborol-5-yl)oxy]benzonitrileAN2728;AN-2728,>=98%;AN2728,Crisaborole;Crisaborole(AN2728);AN2728;AN2728/ANChemicalbook-2728;4-((1-Hydroxy-1,3-dihydrobenzo-[c][1,2]oxaborol-5-yl)oxy)benzonitrile;4-[(1,3-Dihydro-1-hydroxy-2,1-benzoxaborol-5-yl)oxy]benzonitrile

Introduction Criborole (AN2728) is a non-steroidal phosphodiesterase 4 (PDE-4) inhibitor. It was first developed by Anacor Pharmaceuticals. Pfizer acquired Anacor in May 2016. In December of the same year, the U.S. FDA approved criborole (AN2728) ointment (2% or 5%) for local treatment of minor symptoms in patients over 2 years old. Mild to moderate atopic dermatitis, brand name Eucrisa. Product Advantages The biggest advantage of criborole is that it is a small-molecule, non-hormonal drug that can combine therapeutic effect and comfort, and even has almost no side effects for some patients. It is the first external dermatology drug to enter the list of urgently needed clinical new drugs. It can be said that the launch of Criborole has filled the treatment needs of atopic dermatitis in Chinese children and adults, breaking the status quo of no new products in the topical non-hormonal anti-inflammatory field for more than 10 years, and is of epoch-making significance. Market Situation Criborole was developed by Anacor, and Pfizer acquired Anacor at a high price. In December 2016, Criborole was approved by the US FDA for marketing, becoming the first US FDA approval for the treatment of atopic dermatitis (AD) in the past 15 years. a new molecular entity. In July 2020, Criborole Ointment was approved for marketing by Chemicalbook in China, becoming China's first and only hormone-free PDE-4 inhibitor suitable for the treatment of mild to moderate atopic dermatitis in children and adult patients aged 2 years and above. Prescription topical medications. Criborole is an inhibitor of phosphodiesterase 4 (PDE4). PDE4 is an enzyme involved in controlling the activity of inflammatory cells. PDE4 participates in IL-4/5 in inflammatory cells by controlling the degradation of cyclic adenosine monophosphate. The production of inflammatory factors such as /10/13 and prostaglandin PGE2 improves the body's inflammatory response by inhibiting PDE4 activity. Clinical studies have shown that in patients aged 2 to 79 years with mild to moderate atopic dermatitis, treatment with criborole for 28 days resulted in significant relief and complete or near-complete resolution of the rash compared with placebo. Criborole's sales in 2017 were US$67 million; in 2018, its global sales were US$147 million, with a growth rate of 119.40%. It has brought new hope to many patients with atopic dermatitis. Purpose AN2728 has shown potent activity both in vivo and in vitro, and AN2728 is being studied for its anti-inflammatory properties. Also used as pharmaceutical intermediates. Biologically active Crisaborole (AN2728) is a selective small molecule PDE4 inhibitor with broad-spectrum anti-inflammatory activity.

Criborole (AN2728) is a nonsteroidal phosphodiesterase 4 (PDE-4) inhibitor. It was first developed by Anacor Pharmaceuticals. In May 2016, Pfizer acquired AnChemicalbookacor. In December of the same year, the US FDA approved criborole (AN2728) ointment (2% or 5%) for local treatment of minor symptoms in patients over 2 years old. Mild to moderate atopic dermatitis, brand name Eucrisa.